Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
Amir Massarweh(Rabin Medical Center), Salomon M. Stemmer(Tel Aviv University), Dafna Yahav(Sheba Medical Center), Haim Ben‐Zvi(Tel Aviv University), Neta Moskovits(Tel Aviv University), Baruch Brenner(Rabin Medical Center), Noa Eliakim‐Raz(Tel Aviv University), Alexandra Benouaich‐Amiel(Rabin Medical Center), Alona Zer(Rambam Health Care Campus), Adva Levy‐Barda(Rabin Medical Center), Boaz Tadmor(Rabin Medical Center), Tal Zaks(Moderna Therapeutics (United States)), Shlomit Yust‐Katz(Rabin Medical Center), Jihad Bishara(Tel Aviv University), Amos Stemmer(Tel Aviv University)
Cited by 291
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729